FDA Approves Third Treatment for Fibrodysplasia Ossificans Progressiva

◆ ◆ The Wire takeaway

Biotech founders in rare disease now face a smaller barrier to US market entry as the FDA is demonstrating a faster path for critical orphan drug approvals. You can move on developing rare condition treatments with more confidence in regulatory support.